Variable response to the diepoxybutane test in two dizygotic twins with Fanconi's anemia and flow cytometry for diagnosis confirmation

R. Toraldo, G. Canino, C. Tolone, M. D'Avanzo, B. Porfirio, H. Hoehn, T. Schroeder-Kurth, V. Pistoia

Research output: Contribution to journalArticle

Abstract

Fanconi's anemia (FA) is a rare, genetically heterogeneous, autosomal recessive disorder characterized by bone marrow failure, congenital abnormalities, chromosome instability, and increased susceptibility to neoplasia. Congenital abnormalities vary in location and in severity, and not all patients are affected. Although the primary defect of FA is unknown, hypersensitivity to the clastogenic effect of agents that introduce cross- links in the DNA, such as diepoxybutane (DEB), is a marker of the FA phenotype in patients suffering from aplastic anemia without the physical characteristics of the syndrome and, conversely, in cases with abnormalities in the preanemic phase. We report the case of two dizygotic twins suffering from FA with discordant hematologic data. The DEB test repeated several times in various laboratories yielded conflicting results, whereas cell cycle studies by flow cytometry revealed a pattern typical of FA patients. Moreover, the flow cytometric pattern was correlated with the clinical severity of the disease.

Original languageEnglish
Pages (from-to)45-54
Number of pages10
JournalPediatric Hematology and Oncology
Volume15
Issue number1
Publication statusPublished - Jan 1998

    Fingerprint

Keywords

  • Diepoxybutane test (DEB test)
  • Fanconi's anemia
  • Flow cytometry

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation

Cite this

Toraldo, R., Canino, G., Tolone, C., D'Avanzo, M., Porfirio, B., Hoehn, H., Schroeder-Kurth, T., & Pistoia, V. (1998). Variable response to the diepoxybutane test in two dizygotic twins with Fanconi's anemia and flow cytometry for diagnosis confirmation. Pediatric Hematology and Oncology, 15(1), 45-54.